

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

BUSINESS UPDATE FOR DR. FREEMAN® FLU/RSV HOME DIAGNOSTIC KIT

The board of directors (the “**Board**”) of Jacobson Pharma Corporation Limited (the “**Company**” or “**Jacobson Pharma**”, together with its subsidiaries, the “**Jacobson Pharma Group**”) is pleased to announce that Jacobson Medical (Hong Kong) Limited (“**Jacobson**”), a wholly-owned subsidiary of the Company, has launched its first home diagnostic product for influenza and respiratory syncytial virus (“**RSV**”) in the markets of Hong Kong and Macau under the brand name of “Dr. Freeman® Flu/RSV Combo” since January 2020 across different over-the-counter channels comprising the major healthcare chain stores and drug stores.

Dr. Freeman® Flu/RSV Combo (the “**Product**”) is a handy one-step home diagnostic test designed for qualitative determination of specific types of influenza A and B virus and respiratory syncytial virus with test results available in 8 minutes. It uses monoclonal antibodies specific to the corresponding antigens of influenza and RSV for determination of the specific types of influenza and RSV infected, in addition to the indication of the presence of influenza. The Product can help clinicians to promptly start targeted antiviral treatment in patients and formulate effective infection control measures.

The Company believes that the Product can benefit the public by providing a handy, speedy and specific self-diagnostic tool for the communicable disease, which is designed to enable influenza/RSV infected patients to seek effective and prompt medical treatment at the onset of the illnesses.

Reference is also made to the announcement of the Company in relation to a potential spin-off listing of its branded healthcare business (the “**Spin-off Business**”) dated 20 January 2020. Dr. Freeman® Flu/RSV Combo is the first branded health and wellness product launched into the market amongst others in the home diagnostic portfolio of the Spin-off Business. The Group is also in active discussion with overseas suppliers for other diagnostic products to be launched under the brand name of Dr. Freeman®, which the Group will make further announcement to update the investors and the market as and when appropriate.

By order of the Board
Jacobson Pharma Corporation Limited
YIM Chun Leung
Executive Director and Company Secretary

Hong Kong, 5 February 2020

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung (also as Company Secretary) and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Wong Chi Kei, Ian as independent non-executive Directors.